Patent ID: 6441049
Filing Date: 2002-08-27
Classification: A61K,A61P,C07C,C07D,C07F

Abstract:
The method for treating Alzheimer's disease in a subject in need thereof which comprises administering to the subject an amount of a compound of the formula I whereinR1 is hydrogen or C1-C4 alkyl; R2 is selected from hydrogen, C1-C6 alkyl, aryl or C7-C10 aralkyl; R3 is selected from hydrogen, C1-C6 alkyl, C3-C10 alkenyl, C3-C8 cycloalkylC1-C6 alkyl, C1-C6 alkoxycarbonylC1-C6 alkyl, C1-C6 alkylthio, heteroarylC1-C4 alkyl, unsubstituted or substituted aryl or unsubstituted or substituted C7-C10 aralkyl wherein the substituent on the aryl or aralkyl are one or more substituents independently selected from the group consisting of halogen, hydroxy, C1-C6 alkyl and unsubstituted or substituted C1-C6 alkoxy wherein the substituents on the alkoxy are one or more substituents independently selected from amino, C1-C6 alkylamino, C1-C6 dialkylamino, pyrrolidinyl, piperidinyl, azepinyl or morpholinyl; or R2 and R3, together with the nitrogen to which they are attached, form a five or six-membered heterocyclic ring selected from pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or piperazinyl; R4 is C1-C6 alkyl, aryl, or C7-C10 aralkyl; and R5 and R6 are each independently selected from hydrogen, C1-C6 alkyl, C3-C10 alkenyl, C1-C8 alkylcarbonyl, or diphenylphosphinyl; or pharmaceutically acceptable salts thereof; effective to inhibit the binding of an amyloid beta peptide with human alpha-7 nicotinic acetylcholine receptors.